Valuation: Palisade Bio, Inc.

Market Cap 295M 257M 242M 221M 414M 28.16B 414M 2.9B 1.12B 14.38B 1.11B 1.08B 46.35B P/E 2026 *
-7.51x
P/E 2027 * -6.12x
Enterprise Value 197M 172M 162M 148M 277M 18.82B 277M 1.94B 749M 9.61B 739M 723M 30.98B EV / Sales 2026 *
551x
EV / Sales 2027 * -
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * -
1 week-16.13%
Current month-13.33%
1 month-19.52%
3 months-8.15%
6 months-10.58%
Current year-28.09%
1 week 1.58
Extreme 1.585
1.76
1 month 1.58
Extreme 1.585
2.24
Current year 1.45
Extreme 1.45
2.86
1 year 0.64
Extreme 0.64
2.86
3 years 0.53
Extreme 0.53
22.35
5 years 0.53
Extreme 0.53
2,265
10 years 0.53
Extreme 0.53
8,182.5
Manager TitleAgeSince
Chief Executive Officer 68 2022-10-09
President 48 -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 67 2024-02-13
Director/Board Member 55 2018-12-31
Director/Board Member 68 2023-02-01
Date Insider Type Main position Quantity % Market Cap. Importance
8/19/26 Don

Chief Executive Officer

-176,800 0.1066%
7/9/26 Buy

Director

25,000 0.0151%
7/7/26 Buy

Director

30,000 0.0181%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-16.13%+166.18%-79.38% 295M
+2.55%+4.77%+4.07%+32.02% 46.68B
+0.08%+0.16%+43.79%+35.89% 44.42B
+0.66%+6.23%+8.96%+93.14% 41.58B
+0.05%-5.86%+334.27%+542.87% 41.32B
-1.60%+0.56%+10.84%+46.93% 30.14B
+0.96%+1.56%+26.52%+159.67% 17.42B
-0.01%-0.92% - - 15.6B
+1.15%+7.46%+25.97%+43.93% 15.54B
-1.08%+12.11%-10.11% - 14.08B
Average +0.31%-0.11%+67.83%+109.38% 26.71B
Weighted average by Cap. +0.48%+0.94%+69.26%+144.26%

Financials

2026 *2027 *
Net sales 357K 312K 293K 268K 502K 34.14M 502K 3.52M 1.36M 17.44M 1.34M 1.31M 56.21M -
Net income -47.86M -41.83M -39.31M -35.87M -67.33M -4.58B -67.34M -472M -182M -2.34B -180M -176M -7.53B -63.05M -55.1M -51.78M -47.26M -88.69M -6.03B -88.71M -622M -240M -3.08B -237M -232M -9.92B
Net Debt -97.7M -85.38M -80.25M -73.23M -137M -9.34B -137M -963M -372M -4.77B -367M -359M -15.38B -335M -292M -275M -251M -471M -32B -471M -3.3B -1.27B -16.34B -1.26B -1.23B -52.68B
Logo Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Employees
-
Date Price Change Volume
26-09-22 US$1.690 0.00% 4,983,540
26-09-21 US$1.690 +6.29% 3,574,457
26-09-18 US$1.590 -6.47% 6,872,526
26-09-17 US$1.700 +0.59% 5,398,119
26-09-16 US$1.690 -16.13% 8,407,625
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.690USD
Average target price
10.22USD
Spread / Average Target
+504.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PALI Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!